In this episode, we look at AltruBio’s Cinderella story. While the company officially launched in 2020, its roots go back more than 20 years with a rich immunology pipeline stuck in “academic-style experiments.” On the brink of bankruptcy, a team of executives — including Dr. Judy Chou — stepped in to reboot the company, which has since raised nearly $300M.Judy reflects on her journey from med school in Taiwan to Ivy League colleges and senior roles at AbbVie and Bayer before taking the leap into biotech leadership. We talk about AltruBio’s bold pivot into autoimmune disease, how Judy successfully convinced investors to save a sinking ship, her IPO visions for the company, and her mission to keep patients the priority. With Phase IIa ulcerative colitis data expected later this year, the question remains: will this Cinderella story endure?Timestamps:For any comments, questions or feedback you can connect directly with ⁠⁠Surani Fernando⁠⁠ on LinkedIn or email: [email protected]Title music composed by: Yrii Semchyshyn (Coma Media)